CD8A and neoplasm: Treatment of tumor-bearing mice with anti-PD-L1 alone or combined anti-PD-L1 and anti-CTLA-4 leads to the emergence of a population of PD-1+A2AR- CD8+ T cells that correlate with therapeutic outcome.